How to read: Every bubble is one Indian bromhexine exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Bromhexine report covers
KEY TAKEAWAYEvery figure in this report is grounded in real commercial bromhexine trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian bromhexine suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Bromhexine India trade report
P
Product scope
Bromhexine
All variants merged — branded and generic formulations of bromhexine
T
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
S
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
G
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
C
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
R
Shipments analysed
69
Every commercial bromhexine trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY2025-Q4 followed a mixed: Oct $165.6K, Nov $159.0K, Dec $120.8K. Shipment counts rose across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$165.6K
Oct USD
20 shipments
2
$159.0K
Nov USD
-4.0% MoM
3
$120.8K
Dec USD
-24.0% MoM
4
Mixed
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov dipped 4.0% in USD but shipment count kept steady.
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $166K, making it the strongest month by value.
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: UMAVIDA PHARMA PVT LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import bromhexine from India, how much they buy, and who supplies each market
KEY TAKEAWAYAustralia absorbs 15.8% of India’s 2025-Q4 bromhexine trade ($70.5K). Beyond the top 10 destinations, 27 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Asia has 12 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 27 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much bromhexine India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$257K
57.6% of trade
12 countries · 27 shipments
Americas
$12K
2.8% of trade
5 countries · 8 shipments
Africa
$106K
23.8% of trade
9 countries · 25 shipments
Oceania
$70K
15.8% of trade
1 countries · 9 shipments
Fig 4.1 Australia is the #1 corridor ($70K) — 27 flow arcs from India radiate across 4 continents.
How to read: The world map shows every country colored by how much Indian bromhexine it receives (light = low, dark = high). Orange arcs radiate from India to the top 27 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
#
Destination
Total USD
Ships
#1 Indian supplier
USD
#2 Indian supplier
USD
#3 Indian supplier
USD
1
Australia
$70K
9
ADCOCK INGRAM LTD
$45K
GRACURE PHARMACEUTICALS LTD
$17K
MEDREICH LTD
$9K
2
Singapore
$62K
4
ADCOCK INGRAM LTD
$62K
—
—
—
—
3
Angola
$55K
8
UMAVIDA PHARMA PVT LTD
$44K
AURA PHARMACEUTICALS PVT LTD
$6K
AURA LIFECARE PVT LTD
$5K
4
Vietnam
$53K
1
GRACURE PHARMACEUTICALS LTD
$53K
—
—
—
—
5
Nepal
$38K
6
FRANCO-INDIAN PHARMACEUTICALS PVT LTD
$22K
GALPHA LABORATORIES LTD
$16K
—
—
6
Sri Lanka
$31K
1
IPCA LABORATORIES LTD
$31K
—
—
—
—
7
Timor-Leste
$26K
1
PHARMEDA HEALTHCARE PVT LTD
$26K
—
—
—
—
8
Nigeria
$25K
1
LABORATE PHARMACEUTICALS INDIA LTD
$25K
—
—
—
—
9
Kenya
$19K
2
CACHET PHARMACEUTICALS PVT LTD
$19K
—
—
—
—
10
Cambodia
$17K
2
MASCOT HEALTH SERIES PVT LTD
$16K
POORNIMA HEALTHCARE
$677
—
—
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 57.6% of USD — but Australia is the single largest market.
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
15.8%
#1 country share
Australia alone
62.5%
Top 5 share
5 of 27 countries
96.8%
Top 15 share
Long tail of 12 countries = 3.2%
HHI 971
Destination HHI
Competitive spread
27
Countries served
Global pharma reach from India
12
Asia countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
34 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAYADCOCK INGRAM LTD ($106.7K, 24.0% share) and GRACURE PHARMACEUTICALS LTD ($69.2K) together control 39.5% of India’s 2025-Q4 bromhexine trade. The top 5 suppliers hold 62.1%. 34 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian bromhexine suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 ADCOCK INGRAM LTD leads by $38K over GRACURE PHARMACEUTICALS LTD — top 20 Indian exporters ranked by trade value
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: GOD GIFT LABORATORY is #20 by value but #7 by volume.
Fig 5.2 ADCOCK INGRAM LTD also leads by shipment count (8) but ranking shifts for volume-heavy players
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: GOD GIFT LABORATORY moves from #7 by volume to #20 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 34 bromhexine suppliers split into strategic segments
KEY TAKEAWAY9 suppliers (25%) generate 80.4% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 ADCOCK INGRAM LTD and GRACURE PHARMACEUTICALS LTD sit in the leaders zone — high volume AND high value.
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 80.4% of USD — classic concentration.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 2 destinations and up to 2 importers per destination.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 2 destinations and up to 1 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
33 importers across 27 countries — who is buying Indian bromhexine and how much
KEY TAKEAWAYThe demand side is dramatically more fragmented than supply: the top 25 importers together hold only 68.3% of total USD. 94% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian bromhexine. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 HO CHI MINH CITY MEDICAL IMPORT-E is the #1 importer at $53K (11.8%) — top 25 by trade value
How to read: Left semicircle = top 20 Indian suppliers; right = top 20 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian bromhexine prices vary by supplier, country and dosage form
KEY TAKEAWAYBromhexine prices span 13956× ($0.0010 → $14.14). The coefficient of variation is 2.08. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. PHARMEDA HEALTHCARE PVTSourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. ADCOCK INGRAM LTDSourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. Sourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. Sourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAYExtreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
Date
Exporter
Country
Dosage
Qty
USD
$/unit
Why
Nov 2025
AKRITI PHARMACEU…
Turkmenistan
Tablet
43
$607.89
$14.14
Specialty / small-batch
Nov 2025
SAVA HEALTHCARE …
Mauritius
Tablet
1
$12.17
$12.17
Specialty / small-batch
Nov 2025
SAVA HEALTHCARE …
Mauritius
Tablet
1
$12.17
$12.17
Specialty / small-batch
Nov 2025
SAVA HEALTHCARE …
Mauritius
Tablet
1
$12.07
$12.07
Specialty / small-batch
Nov 2025
SAVA HEALTHCARE …
Mauritius
Tablet
2
$24.12
$12.06
Specialty / small-batch
Oct 2025
GOGA HEALTHCARE
Tajikistan
Tablet
610
$4K
$7.06
Specialty / small-batch
Dec 2025
BLUE CROSS LABOR…
Myanmar
Tablet
383
$2K
$5.95
Specialty / small-batch
Dec 2025
ADCOCK INGRAM LTD
Australia
Tablet
5K
$11K
$2.28
Specialty / small-batch
Nov 2025
ADCOCK INGRAM LTD
Australia
Tablet
6K
$14K
$2.23
Specialty / small-batch
Dec 2025
GRACURE PHARMACE…
Australia
Syrup
14K
$17K
$1.15
Specialty / small-batch
↓ TOP 10 LOWEST USD/UNIT
Date
Exporter
Country
Dosage
Qty
USD
$/unit
Why
Oct 2025
CACHET PHARMACEU…
Tanzania
Syrup
395
$0.400
$0.0010
Small sample / trial shipment
Dec 2025
DEN MARK PHARMAC…
Somalia
Syrup
100
$0.137
$0.0014
Small sample / trial shipment
Dec 2025
DEN MARK PHARMAC…
Somalia
Syrup
50
$0.097
$0.0019
Small sample / trial shipment
Dec 2025
YELURI FORMULATI…
Burundi
Solution
10K
$28.05
$0.0028
Dec 2025
PRAHEM LABORATOR…
Panama
Syrup
30K
$88.84
$0.0030
Dec 2025
EVOLET HEALTHCAR…
Tajikistan
Syrup
20K
$114.98
$0.0059
Dec 2025
CAPLIN POINT LAB…
Guatemala
Syrup
12K
$92.92
$0.0078
Dec 2025
POORNIMA HEALTHC…
Cambodia
Tablet
17K
$676.99
$0.040
Oct 2025
AURA PHARMACEUTI…
Angola
Tablet
31K
$3K
$0.100
Oct 2025
AURA PHARMACEUTI…
Angola
Tablet
31K
$3K
$0.100
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
Dosage form is the #1 price driver, not destination
Light cells = easy-entry markets for small suppliers
Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship bromhexine, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAYBromhexine leaves India through 16+ ports. The top 5 (BANGALORE ICD, NHAVA SHEVA SEA (JNPT), PATLI ICD) handle 82.7% of total USD. ICD moves 39% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 BANGALORE ICD handles $116K — top 16 Indian origin ports by trade value.
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
Route
Mode
Transit time
Notes
NHAVA SHEVA SEA (JNPT) → US East Coast
Sea
22–28 days
Via Suez; 2–3 transshipments typical
NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria)
Sea
18–24 days
Direct liner service available
MUMBAI AIR (SAHAR) → New York JFK
Air
3–5 days
Direct cargo; cold-chain available
MUNDRA SEA → Rotterdam
Sea
20–26 days
Via Suez; Hamburg also served
HYDERABAD AIR → London Heathrow
Air
2–4 days
Pharma-grade cargo corridor
CHENNAI SEA → Chittagong (Bangladesh)
Sea
7–12 days
Short-sea route; high frequency
RAXAUL → Birgunj (Nepal)
Road
1–2 days
Land border crossing
NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya)
Sea
14–20 days
Direct or via Colombo hub
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAYICD dominates at 39% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
ICD
$316K
70.9% of USD · 39.1% of ships
SEA
$90K
20.2% of USD · 36.2% of ships
ROAD
$38K
8.5% of USD · 8.7% of ships
AIR
$2K
0.3% of USD · 15.9% of ships
Fig 8.3 The dominant corridor is BANGALORE ICD → Sea → Asia ($62K).
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAYMauritius is the most concentrated destination (HHI 10000, 1 suppliers). Australia is the most competitive (HHI 4800).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Mauritius (HHI 10,000) is the most concentrated — Australia (HHI 4,800) is the most competitive.
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 20 of 20 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
Buyer
Country
Sole supplier
USD
Ships
Risk
HO CHI MINH CITY MED…
Vietnam
GRACURE PHARMACE…
$53K
1
MEDIUM
INOVA PHARMACEUTICAL…
Australia
ADCOCK INGRAM LTD
$45K
4
MEDIUM
INOVA PHARMACEUTICAL…
Singapore
ADCOCK INGRAM LTD
$31K
2
MEDIUM
EMAR PHARMA (PVT) LTD
Sri Lanka
IPCA LABORATORIE…
$31K
1
MEDIUM
UTL PHARMACY PVT LTD
Nepal
FRANCO-INDIAN PH…
$22K
4
MEDIUM
NOUMED PHARMACEUTICA…
Australia
GRACURE PHARMACE…
$17K
1
MEDIUM
SOVINA PHARMACEUTICA…
Cambodia
MASCOT HEALTH SE…
$16K
1
MEDIUM
GUNJESHWARI PHARMA
Nepal
GALPHA LABORATOR…
$16K
2
MEDIUM
Conclusion: 31 buyers depend on exactly one Indian supplier, representing $305K in trade. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
Buyer
Country
Suppliers
USD
Dominant
Resilience
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
Country
Tier
Lead
Price
Risk
Entry approach
Australia
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Singapore
Tier 3 (emerging)
14–28 days (sea)
$0.10–$1/unit
LOW
First-mover advantage
Angola
Tier 3 (emerging)
14–28 days (sea)
$0.10–$1/unit
LOW
First-mover advantage
Vietnam
Tier 3 (emerging)
14–28 days (sea)
$0.10–$1/unit
LOW
First-mover advantage
Nepal
Tier 3 (emerging)
14–28 days (sea)
$0.10–$1/unit
LOW
First-mover advantage
Sri Lanka
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Timor-Leste
Tier 3 (emerging)
14–28 days (sea)
$0.10–$1/unit
LOW
First-mover advantage
Nigeria
Tier 3 (emerging)
14–28 days (sea)
$0.10–$1/unit
LOW
First-mover advantage
Kenya
Tier 3 (emerging)
14–28 days (sea)
$0.10–$1/unit
LOW
First-mover advantage
Cambodia
Tier 3 (emerging)
3–5 days (air)
$0.10–$1/unit
LOW
First-mover advantage
Myanmar
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Tajikistan
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Venezuela
Tier 3 (emerging)
14–28 days (sea)
$0.10–$1/unit
LOW
First-mover advantage
Suriname
Tier 3 (emerging)
14–28 days (sea)
$0.10–$1/unit
LOW
First-mover advantage
DR Congo
Tier 3 (emerging)
14–28 days (sea)
$0.10–$1/unit
LOW
First-mover advantage
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 13 in Fragile Dependency (concentrated + shrinking).
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 15 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAYQuick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 15 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
ID
Action
Timing
Impact
A1
Pitch top single-source buyer in Vietnam
This Q
HIGH
A2
Offer alternative to top multi-source buyer
This Q
HIGH
A3
Audit Mauritius lock-ins (HHI 10000)
This Q
MED
A5
Enter Tanzania (2 suppliers)
This Q
HIGH
A6
Enter Australia (3 suppliers)
This Q
MED
A8
Build Singapore distribution
6–12m
HIGH
A9
Bundle injection/infusion catalog for premium markets
6–12m
MED
B
FOR BUYERS
ID
Action
Timing
Impact
A4
Monitor rising exporters (climbers)
This Q
MED
A7
Register for Australia tenders
6–12m
HIGH
A10
Track quarterly HHI shifts across key destinations
This Q
LOW
A11
Map competitor buyer portfolios quarterly
This Q
MED
A12
Qualify second source for single-source buyers
This Q
MED
§9.4 Easy-entry markets — 15 countries with ≤5 Indian suppliers
#
Country
Region
Suppliers
Q4 USD
Growth
Barrier
Why this is easy
1
Tanzania
Africa
2
$3K
+654053.9%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
2
Australia
Other
3
$70K
0%
LOW
Low competition (3 suppliers), accessible market
3
Singapore
Asia
1
$62K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
4
Angola
Africa
3
$55K
-89%
LOW
Low competition (3 suppliers), accessible market
5
Vietnam
Asia
1
$53K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
6
Nepal
Asia
2
$38K
+32.4%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
7
Sri Lanka
Asia
1
$31K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
8
Timor-Leste
Asia
1
$26K
-100%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
9
Nigeria
Africa
1
$25K
-100%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
10
Kenya
Africa
1
$19K
-100%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
11
Cambodia
Asia
2
$17K
-95.9%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
12
Myanmar
Asia
2
$11K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
13
Tajikistan
Asia
3
$8K
-17.3%
LOW
Low competition (3 suppliers), accessible market
14
Venezuela
Other
1
$7K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
15
Suriname
Other
1
$5K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
This report covers 69 2025-Q4 Bromhexine shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/bromhexine
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAYThis section contains every one of the 69 2025-Q4 bromhexine shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian bromhexine shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
69
across all regions
TOTAL USD
$445K
2025-Q4 FOB value
UNITS
1.1M
tablets, capsules, etc.
SUPPLIERS
34
Indian exporters
BUYERS
33
global importers
COUNTRIES
27
destinations
§10.2 Regional breakdown
Africa
$106K
23.8%
9 ctry · 25 ships
Asia
$257K
57.6%
12 ctry · 27 ships
Americas
$12K
2.8%
5 ctry · 8 ships
Oceania
$70K
15.8%
1 ctry · 9 ships
§10.3 Key insights from the data
🌍
Africa is the largest region at $106K (23.8%), spanning 9 countries.
🏢
34 Indian suppliers shipped to 33 buyers across 27 countries — average shipment value $6K.
📄
Top 0 markets: .
🔍
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
All 31 global bromhexine importers — complete list ranked by USD
KEY TAKEAWAYThis directory lists every company that imported Indian bromhexine in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
#
Buyer
Country
Ships
USD
Primary supplier
Dosage forms
1
HO CHI MINH CITY MEDICAL IMPORT-E
Vietnam
1
$53K
GRACURE PHARMACEUTIC…
Tablet
2
INOVA PHARMACEUTICALS (AUSTRALIA)
Australia
4
$45K
ADCOCK INGRAM LTD
Tablet
3
INOVA PHARMACEUTICALS (SINGAPORE)
Singapore
2
$31K
ADCOCK INGRAM LTD
Tablet
4
EMAR PHARMA (PVT) LTD
Sri Lanka
1
$31K
IPCA LABORATORIES LTD
Elixir
5
UTL PHARMACY PVT LTD
Nepal
4
$22K
FRANCO-INDIAN PHARMA…
Syrup
6
NOUMED PHARMACEUTICALS PTY LTD
Australia
1
$17K
GRACURE PHARMACEUTIC…
Syrup
7
SOVINA PHARMACEUTICALS CO LTD
Cambodia
1
$16K
MASCOT HEALTH SERIES…
Syrup
8
GUNJESHWARI PHARMA
Nepal
2
$16K
GALPHA LABORATORIES …
Syrup
9
ABACUS PHARMA (A) LTD
Kenya
1
$11K
CACHET PHARMACEUTICA…
Syrup
10
MEDREICH AUSTRALIA PTY LTD
Australia
4
$9K
MEDREICH LTD
Tablet
11
BIO SYSTEM (BIOSYS) CO LTD
Myanmar
1
$9K
EURO BIOGENICS
12
PHILLIPS THERAPEUTICS LTDPHILLIPS B
Kenya
1
$7K
CACHET PHARMACEUTICA…
expectorant
13
TOTHE ORDER SHARJAH UNITED ARAB EMI
Angola
2
$6K
AURA PHARMACEUTICALS…
Tablet
14
LUA COMERCIO GERAL LIMITADA
Angola
1
$5K
AURA LIFECARE PVT LTD
Syrup
15
HEERAMAN TRADING NV
Suriname
2
$5K
AASHIRWAD PHARMA INT…
Syrup
16
UNIQUE PHARMA
DR Congo
1
$5K
BIOMATRIX HEALTHCARE…
Syrup
17
GOLDEN BRIGHT FUTURE CO LTD
Thailand
1
$4K
BOHRA LIFESCIENCE PV…
Tablet
18
DERDE DERMAN
Turkmenistan
3
$4K
GOD GIFT LABORATORY …
Syrup, Tablet
19
ARAUPHAR S.A
Tanzania
1
$3K
AURA LIFECARE PVT LTD
Syrup
20
DALIAN FAIRUS TRADING CO LTD
China
1
$3K
FAMN PHARMA PVT LTD
Tablet
21
SIN PHYU KYUN COMPANY LTD
Myanmar
1
$2K
BLUE CROSS LABORATOR…
Tablet
22
NATIONAL CENTER FOR TUBERCULOSIS
Cambodia
1
$676.99
POORNIMA HEALTHCARE
Tablet
23
TURKMENDERMANSENAGAT ASSOCIATION
Turkmenistan
1
$607.89
AKRITI PHARMACEUTICA…
Tablet
24
THE PURHCASE MANAGER
Cayman Islands
1
$159.83
KALINDI OVERSEAS
Tablet
25
DUSTI PHARM LLC
Tajikistan
1
$114.98
EVOLET HEALTHCARE PV…
Syrup
26
FARMA SOLUTION SOCIEDAD ANONIMA
Guatemala
1
$92.92
CAPLIN POINT LABORAT…
Syrup
27
REGENCY EXIM TRADE LTD
Mauritius
4
$48.64
SAVA HEALTHCARE LTD
Tablet
28
PRISM INTERNATIONAL LLC
Seychelles
1
$29.29
MEDMALL PHARMACY PVT…
Tablet
29
LOTUS PHARMA
Burundi
1
$28.05
YELURI FORMULATIONS …
Solution
30
EMIRATES POST COMPANY
United Arab Emirates
1
$1.86
LAWRENCE WALTER
Tablet
31
ALCHEM INDUSTRIESB.P
Tanzania
1
$0.400
CACHET PHARMACEUTICA…
Syrup
This report covers 69 2025-Q4 Bromhexine shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/bromhexine
Talk to our trade analyst
Need a custom bromhexine report or a deeper dive into any market? Our team is ready.